TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
25 août 2017 08h01 HE
|
TESARO, Inc.
WALTHAM, Mass., Aug. 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data from nine abstracts will be presented at the...
Angiochem's ANG1005 Shows Clinical Benefits and Prolonged Survival for Breast Cancer Patients With Brain Metastases
17 oct. 2016 07h00 HE
|
Angiochem
MONTREAL, QC--(Marketwired - October 17, 2016) - Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, recently presented data...
OncoMed Presents Interim Phase 1b Data for Ipafricept and Vantictumab in Pancreatic Cancer at the ESMO 2016 Congress
10 oct. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
COPENHAGEN, Denmark and REDWOOD CITY, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) today announced the presentation of interim clinical data from its...
TESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016
08 oct. 2016 02h15 HE
|
TESARO, Inc.
Simultaneous presentation of data at ESMO and publication online in the New England Journal of MedicineTESARO Investor Webcast to be Held at 7:00 PM CET / 1:00 PM EDT COPENHAGEN, Oct. 08, 2016 ...
Adaptimmune to Provide Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress
05 oct. 2016 16h30 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Oct. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announced that it will present a...
Angiochem to Present at ESMO 2016 Congress
03 oct. 2016 07h00 HE
|
Angiochem
MONTREAL, QC--(Marketwired - October 03, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make a...
OncoMed to Present Clinical Data for Wnt Inhibitors at the ESMO 2016 Congress
29 sept. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 29, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present interim data from Phase 1b clinical trials of the company’s Wnt...
Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress
21 sept. 2016 08h05 HE
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...